Efficacy News and Research

RSS

Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA

Protalex, Inc., a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.

20 Aug 2010

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries.

20 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.

20 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Opinions: Aid to Pakistan; Criteria for effective aid

A New York Times editorial about the flooding in Pakistan and the global response to it, cautions: "The world, especially the United States, must not blow this one. We worry it already could be doing that."

18 Aug 2010

USPTO grants IRIDEX patent for MicroPulse technology in laser eye surgery

IRIDEX Corporation today announced the receipt of issuance of U.S. Patent No. 7,771,417, titled "Laser System with Short Pulse Characteristics And Its Method Of Use." This patent applies to the company's MicroPulse™ technology which provides the ophthalmologist with fine dose control of laser energy during eye surgery. Ophthalmologists are using MicroPulse technology to treat patients suffering from diabetic retinopathy and other sight-threatening retinal and glaucoma disorders.

18 Aug 2010

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN trial of the Company's CARILLON Mitral Contour System will be presented at the European Society of Cardiology 2010 Congress on August 29, 2010 in Stockholm.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Study finds pharmaceuticals as a two-tier market for producing 'lemons' and serious harm

The pharmaceutical industry is a "market for lemons," a market in which the seller knows much more than the buyer about the product and can profit from selling products less effective and less safe than consumers are led to believe, according to an analysis that will be presented at the 105th Annual Meeting of the American Sociological Association.

18 Aug 2010

Study deems gentamicin-collagen sponge ineffective in reducing sternal wound infections

Contradicting previous study results, insertion of a sponge that contains the antibiotic gentamicin at the time of surgical closure following cardiac surgery did not reduce the rate of sternal wound infections after 3 months, compared to patients who did not receive the intervention, according to a study in the August 18 issue of JAMA.

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain Plasticity Inc., a new technology incubator dedicated to the discovery and development of novel technologies that harness the basic principles of brain plasticity to improve the lives of people with neurological and psychiatric disorders, was recently awarded $3.65 million dollars in two separate grants from the National Institutes of Health (NIH).

18 Aug 2010

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

18 Aug 2010

Acupuncture not superior to sham acupuncture in knee osteoarthritis

17 Aug 2010

Study finds sham acupuncture superior to traditional Chinese acupuncture in osteoarthritis treatment

Researchers from MD Anderson Cancer Center determined patients with osteoarthritis (OA) of the knee who are treated with traditional Chinese acupuncture (TCA) do not experience any more benefit than those receiving sham acupuncture (placebo). The team did find that the communication style of the acupuncturist could have a significant effect on pain reduction and satisfaction in patients. Full findings are now online and will publish in the September print issue of Arthritis Care & Research, a journal of the American College of Rheumatology.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

Efficacy News and Research

Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Opinions: Aid to Pakistan; Criteria for effective aid

USPTO grants IRIDEX patent for MicroPulse technology in laser eye surgery

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

FDA grants orphan drug designation to NephRx's lead product NX001

Study finds pharmaceuticals as a two-tier market for producing 'lemons' and serious harm

Study deems gentamicin-collagen sponge ineffective in reducing sternal wound infections

NACTN receives grant to expand spinal cord injury research

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

Acupuncture not superior to sham acupuncture in knee osteoarthritis

Study finds sham acupuncture superior to traditional Chinese acupuncture in osteoarthritis treatment

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News